Merck KGaA (MKGAF) Financials
MKGAF Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| March 31, 2026 | 61.0 billion | 26.7 billion |
| Dec. 31, 2025 | 61.1 billion | 27.5 billion |
| Sept. 30, 2025 | 70.1 billion | 30.2 billion |
| June 30, 2025 | 55.8 billion | 22.4 billion |
MKGAF Free Cash Flow and Stock based compensation
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| March 31, 2026 | 419.9 million | ? |
| Dec. 31, 2025 | 1.0 billion | ? |
| Sept. 30, 2025 | 1.6 billion | ? |
| June 30, 2025 | 145.0 million | ? |
MKGAF Net Income
| Date | Net Income |
|---|---|
| March 31, 2026 | 759.2 million |
| Dec. 31, 2025 | 374.4 million |
| Sept. 30, 2025 | 1.1 billion |
| June 30, 2025 | 772.0 million |
MKGAF Cash and Debt
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| March 31, 2026 | 3.2 billion | 12.4 billion | - |
| Dec. 31, 2025 | 3.2 billion | 12.0 billion | 616.1 million |
| Sept. 30, 2025 | 3.4 billion | 14.4 billion | - |
| June 30, 2025 | 1.9 billion | - | - |
MKGAF Shares Outstanding
MKGAF Expenses
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| March 31, 2026 | 521.1 million | 756.9 million | 1.6 billion | - |
| Dec. 31, 2025 | 491.7 million | 779.2 million | 1.8 billion | - |
| Sept. 30, 2025 | 520.5 million | 908.9 million | 1.7 billion | 1.3 billion |
| June 30, 2025 | 523.3 million | 635.3 million | 1.7 billion | 1.3 billion |
MKGAF Cost of Revenue
| Date | Revenue | Cost of Revenue |
|---|---|---|
| March 31, 2026 | 5.9 billion | 2.4 billion |
| Dec. 31, 2025 | 6.2 billion | 2.7 billion |
| Sept. 30, 2025 | 6.2 billion | 2.5 billion |
| June 30, 2025 | 6.2 billion | 2.6 billion |
MKGAF
Price: $163.78
Dividend Yield: 1.73%
Forward Dividend Yield: 1.15%
Payout Ratio: 35.47%
Dividend Per Share: 1.88 USD
Earnings Per Share: 6.77 USD
P/E Ratio: 20.78
Exchange: PNK
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Market Capitalization: 64.9 billion
Average Dividend Frequency: 1
Years Paying Dividends: 31